Publications
Detailed Information
Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Anna | - |
dc.contributor.author | Choi, Se Rim | - |
dc.contributor.author | Han, Minji | - |
dc.contributor.author | Ha, You-Jung | - |
dc.contributor.author | Lee, Yun Jong | - |
dc.contributor.author | Lee, Eun Bong | - |
dc.contributor.author | Kang, Eun Ha | - |
dc.date.accessioned | 2022-10-07T00:41:06Z | - |
dc.date.available | 2022-10-07T00:41:06Z | - |
dc.date.created | 2022-09-15 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | Seminars in Arthritis and Rheumatism, Vol.56, p. 152080 | - |
dc.identifier.issn | 0049-0172 | - |
dc.identifier.uri | https://hdl.handle.net/10371/185528 | - |
dc.description.abstract | Background: To re-evaluate comparative cardiovascular (CV) safety of febuxostat versus allopurinol among pa-tients with gout following recent accumulated use of febuxostat.Methods: Using 2011-2019 Korea National Health Insurance database, we conducted a cohort study comparing gout patients initiating febuxostat versus allopurinol, 1:1 matched on a propensity-score (PS) for >60 covariates. The primary outcome was a composite endpoint of myocardial infarction, coronary revascularization, and stroke. Secondary outcomes were individual components of the primary outcome, hospitalized heart failure, and all -cause mortality. Subgroup analyses were done for those at high CV risk, long-term users (follow-up >3 years), and those without chronic kidney disease. We used Cox proportional hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Results: We included 160,930 PS-matched pairs of febuxostat and allopurinol users (mean age 59.3 years, 79.6% male). Incidence rates of the primary outcome were 2.06 and 2.27 per 100 person-years for febuxostat and allopurinol users, respectively, with a HR [95% CI] of 1.03 [0.95-1.12] comparing febuxostat versus allopurinol initiators. We also observed similar risks for secondary outcomes, except for reduced all-cause mortality among febuxostat users (HR [95% CI] of 0.84 [0.78-0.91]). Subgroup analyses also showed non-inferior CV safety of febuxostat.Conclusion: In this population-based cohort study including the largest number of febuxostat users to date, we found non-inferior CV safety of febuxostat versus allopurinol. There was a 16% reduction in all-cause mortality among febuxostat users. | - |
dc.language | 영어 | - |
dc.publisher | W. B. Saunders Co., Ltd. | - |
dc.title | Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.semarthrit.2022.152080 | - |
dc.citation.journaltitle | Seminars in Arthritis and Rheumatism | - |
dc.identifier.wosid | 000849117700007 | - |
dc.identifier.scopusid | 2-s2.0-85135950220 | - |
dc.citation.startpage | 152080 | - |
dc.citation.volume | 56 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Yun Jong | - |
dc.contributor.affiliatedAuthor | Lee, Eun Bong | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.